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received 16 cycles. A total of 61 pts (19%) discontinued
treatment due to adverse events. Thirty-ﬁve pts (11%) are
known to have died; 31 deaths occurred after disease pro-
gression. One death occurred within 30 days of last dose and
was considered disease-related.
Conclusions: Based upon a planned interim safety and fu-
tility analysis, the IDMC recommended that the AETHERA
trial continue per protocol.149
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High Dose melphalan (200 mg/m2, Mel200) is the standard
conditioning for autologous stem-cell transplant (ASCT) in
multiple myeloma (MM) patients. Forty percent of MM pa-
tients experience some degree of renal insufﬁciency.
Although common practice, there is no standard for dose
reduction in melphalan due to renal impairment. In addition,
there is no clear correlation between melphalan pharmaco-
kinetics in renal failure and outcome in these patients. Here
we report the impact of renal impairment on response and
toxicity outcomes in patients receiving Mel200 as part of
ASCT.
We identiﬁed 111 patients who received Mel200 and ASCT
between 2001 and 2012 at the University of Illinois. Overall,
the majority of patients were African American (60%). Pa-
tients were stratiﬁed by renal function (n¼35 CrCl <60 ml/
min and n¼76 CrCl  60 ml/min). Baseline characteristics
were equal between the 2 groups aside from age (63.2 years
 8.8 vs. 56.8  8.8. P¼.0004). Patients with renal failure
experienced a signiﬁcantly longer time to engraftment
(12.2 days  3.51 vs. 10.6 days  1.7, P¼.0025) and duration
of diarrhea (6.6 days  6.3 vs. 4 days  3.7. P¼.007). Length
of hospital stay was similar between the two groups (17.6
days  4.5 vs. 16.25 days  5.2. P¼.21). Patients with renal
failure spent an average of 10.6 days on total parenteral
nutrition, compared to 7.27 days in patients with normal
renal function (P¼ns). There were no deaths related to
transplant related mortality in either group. . There was no
difference in response rates between the 2 groups in
terms of complete response (50% in CrCl<60ml/min vs. 40%
in Cr Cl > 60ml/min,P¼ns) or overall response rate at day
+90 (75% in CrCl<60ml/min vs. 100% in Cr Cl > 60ml/
min,P¼ns).
This data demonstrates an increase in drug-related toxicities
of diarrhea, and time on TPN in patients with renal impair-
ment conditioned with HD Mel. We hypothesize that this is
due to reduced renal drug clearance. In addition, longer time
to engraftment in the renal failure group may be a result of
greater overall melphalan exposure. In light of the large
numbers of patients impacted by this data, we suggest that
this would be an ideal patient group for the development of
pharmacokinetic based strategies for individual patient
dosing.150
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Background: Pneumocystis jirovecii pneumonia (PJP) is a
potentially life-threatening disease in immunocompromised
patients. The at-risk population includes patients with HIV
infection and low CD4 counts, hematological malignancies,
hematopoietic stem cell (HSC) and solid organ transplant
recipients, and patients receiving glucocorticoids or other
immunomodulatory agents. The highest-risk group of
immunocompromised patients tends to be those with HIV
(human immunodeﬁciency virus) infection, where PJ follows
an indolent course. However, in non-HIV immunocompro-
mised patients, such as HSC transplant recipients, the
infection tends to present with respiratory failure. The inci-
dence of PJP in autologous BMT (bone marrow transplant)
has not been clearly determined, and the indication for
prophylaxis in this setting remains unclear. In this study we
evaluate the incidence of PJP over a 10-year period in re-
cipients of autologous transplants.
Methods: A retrospective analysis of 1191 consecutive
autologous HSC transplants (1-75 years) performed between
1/1/2000 and 6/30/2011 at the University of Michigan BMT
Program. The data was obtained from BMT Program Data-
base at The University of Michigan Comprehensive Cancer
Center. The diagnosis of PJP was established by bronchoscopy
with brochoaveolar lavage (BAL) with polymerase chain re-
action (PCR). We analyzed the following risk factors for the
development of PJP: diabetes, glucocorticoids, infections,
cutaneous T-cell lymphoma, hypertension, and seizure
disorder.
Results: A total number of 5 PJ infections were diagnosed
during study period, resulting in a cumulative incidence of
0.42% (95%CI [0.136449%–0.976969%]) over 10 year period.
All cases occurred between 2001 and 2006, and 3 months or
later following transplantation. Most patients (n¼4) were
older than 50 years old, and all of them were on steroids.
Diagnoses included non-Hodgkin’s lymphoma (n¼3),
Hodgkin’s lymphoma (n¼1) and multiple myeloma (n¼1).
Conditioning regimen was BEAM (BCNU, etoposide, cytar-
abine, melphalan, n¼4) and high dose melphalan (n¼1).
Only 2/5 patients were neutropenic at the time of the
pneumonia, and this did not correlate with the CD34+ cell
infused, which was 2.2x10E6/kg for all patients. Four pa-
tients were on corticosteroids for relapsed lymphoma (n¼2),
ITP (n¼1), BCNU pneumonitis (n¼1). The remainder patient
was on ﬂorinef and was coinfected with candida and herpes
virus. There were no particular comorbidities associated
with the diagnosis of PJ pneumonia. One patient died of PJ,
the remainder were treated successfully.
Conclusions: Our retrospective analysis of a large cohort of
autologous transplant recipients reveals an extremely low
Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127 S117incidence of PJP, suggesting that PJP prophylaxis is not
routinely warranted in this patient population. Patients who
require systemic corticosteroids posteHSC may be consid-
ered for PJ prophylaxis.151
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There is little consensus regarding the optimal conditioning
regimen for AHCT for NHL. Thiotepa is an alkylating agent
with anti-lymphoma properties, but it has limited data as a
conditioning agent for AHCT in adult NHL. We report here
long-term results of our institutional experience in NHL
receiving AHCT following HDT with etoposide, cyclophos-
phamide and thiotepa (VP-16/CY/TT). Patients received eto-
poside 1800mg/m2 IV x 1 dose, cyclophosphamide (50mg/
kg/dose IV x 3-4 doses), and thiotepa (250mg/m2/dose e
300mg/m2/dose x 3 doses). Forty-three patients were con-
sented and enrolled from November 1997 to June 2009.Table 1
Baseline Demographics
Characteristics N¼43
Median age, years (range) 55 (27-69)
Male gender, n (%) 22 (51%)
Diagnosis (%)
Diffuse Large B-cell Lymphoma (DLBCL) 23 (54%)
Follicular Lymphoma 7 (16%)
Transformed follicular lymphoma 2 (5%)
Mantle Cell Lymphoma 4 (9%)
T-cell NHL 7 (16%)
Bone Marrow Involvement 10 (23%)
CNS Involvement 2 (5%)
Stage
Early Stage (1&2) 14 (32%)
Advanced Stage (3&4) 27 (63%)
Missing 2 (5%)
IPI
Low (0-1) 17 (40%)
Intermediate (2-3) 23 (54%)
High (4-5) 2 (5%)
Unknown 1 (2%)
Prior therapies, median (range) 2 (1-4)
Remission status before transplant
Complete Remission 1 8 (19%)
Complete Remission 2 17 (40%)
Complete Remission 3 2 (5%)
Partial Remission 16 (37%)
Autologous stem cell source (%)
Peripheral Blood 35 (81%)
Bone Marrow 4 (9%)
Both 4 (9%)
Karnofsky Performance Status,
median (range)
90 (80-100)
Median CD34 cell dose infused (106 cells/kg
recipient), (range)
5.3 (1.8-10.5)Disease characteristics are described in Table 1. Peripheral
blood stem cell mobilization utilized cyclophosphamide
and ﬁlgrastim. All patients received antibacterial, antiviral
(acyclovir), and antifungal (ﬂuconazole) prophylaxis along
with ﬁlgrastim support after stem cell infusion. Median
follow up for surviving patients was 4.7 years (range 0.26
years to 15.85 years). Median time to neutrophil and platelet
engraftment was 13 and 21 days, respectively. Signiﬁcant
regimen-related toxicities included mucositis (51%), neu-
tropenic fever (72%), diarrhea (26%), and pneumonia (9%).
No CNS failures were reported. Secondary malignancies
occurred in 3 patients (7%) e two of which were soft tissue
sarcomas and one MDS/AML. Progression free survival (PFS)
and overall survival (OS) at 5 years was 53% (39% - 71%) and
73% (60% - 89%), respectively. Relapse rates at day +100 and 5
years were 9.4% (95% CI: 2.9% e 20.4%) and 40.1% (95% CI:
24.7% - 55.1%), respectively. Cumulative incidence of non-
relapse mortality at day +100 and 5 years was 4.7% (95% CI:
0.8% - 14.0%) and 7% (95% CI: 1.8% - 17.4%), respectively. VP-
16/Cy/TT is a well-tolerated conditioning regimen for pa-
tients with NHL, with promising long term progression-free
and overall survival rates.152
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We performed a retrospective analysis on patients who un-
derwent PBSC collection and subsequent ASCT at our insti-
tution to assess whether efﬁciency of PBSC mobilization is
predictive of engraftment failure.
Methods: We identiﬁed 369 patients who underwent PBSC
collection between 01/01/2006-8/31/2012 for a ﬁrst ASCT.
We collected data on age, sex, use of lenalidomide or
thalidomide (“Imid”) prior to mobilization, mobilization
regimen, # of collections for ﬁnal cell dose, # of CD34+ cells
infused, and the presence of a positive blood culture within
30 days of ASCT. Quintiles were created for the # of CD34+
cells collected. The primary outcomewas engraftment failure
deﬁned as not achieving an absolute neutrophil count (ANC)
>1000/mL or a platelet count >50,000/mL (no platelet
transfusion in </¼ 7 days) by day 30 post-ASCT. Secondary
outcomes were time to ANC and platelet engraftment. We
performed a multivariate logistic regression analysis to
assess the association of collected CD34+ cells and engraft-
ment failure while adjusting for the other variables. For time
to event analyses we used Cox proportional hazard models.
Results: Median patient age was 58 and 56% were male.
Patient-reported race was: Black (38%), White (17%), and
“Other” (45%). Indications for ASCT were Multiple Myeloma
(45%), Non-Hodgkin Lymphoma (41%), Acute Leukemia (9%),
Hodgkin Lymphoma (3%), Amyloidosis (1%), and Germ Cell
Tumors (1%). The median # of CD34+ cells collected was
7.7x10
ˇ
6/kg (range 2.26-120 x10
ˇ
6/kg) and median # of
CD34+ cells infused was 5.3x10
ˇ
6/kg (2.3-45x10
ˇ
6/kg).
Median # of collections for transplant dosewas 2 (range 1-8).
CD34 cells collected were divided into quintiles (cut points:
6.04, 7.57, 9.86 and 17.7x10
ˇ
6/kg). We found that a higher #
of collected CD34+ cells during mobilization was associated
with less engraftment failure (p¼.0067): every increase in
